Clinical Trial Update: Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma [Phase 1]

View source ↗

Summary

Phase 1 trial of Mesothelin-Specific T-Cells (FH-TCR-Tmesothelin) for metastatic pancreatic ductal adenocarcinoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• FH-TCR-Tmesothelin

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 | Phase 1 | Status: TERMINATED